Make Sure Your Alarm Is Set…
This early morning trade is constantly overlooked, but those who use it are retiring early!

Hi, I’m trading expert Dave Aquino and with my new guide, “How To Master The Retirement Trade”, you could be taking advantage of it as well!

The trade starts at 9:30EST…don’t be late!

Get a copy here!

>>>
Bradley L. Campbell, insider at Amicus Therapeutics

Bradley L. Campbell Insider Information

Bradley Campbell is the president and chief operating officer at Amicus, a biopharmaceutical company at the forefront of therapies for rare and orphan diseases. He also serves on the company’s board of directors. He has held the president and COO roles since 2015.

Campbell joined the company in 2006 as senior director of business development, and he currently directs the global commercial organization in charge of the design, strategy and execution of the Galafold™ launch. Additionally, he presides over the market access, technical operations and program management functions of the business. Before joining Amicus, he held commercial and business development positions with Genzyme and Bristol-Myers Squibb, as well as serving as business strategy consultant with Marakon Associates.

In addition to his role with Amicus, Campbell is involved with numerous boards and other charitable groups. He currently sits on the board of ARYA Sciences Acquisition Corp III, the Association for Regenerative Medicine (ARM), BioNJ and the corporate advisory board for the National Tay-Sachs and Allied Diseases Association. He previously served on the board for Progenics Pharmaceuticals.

Campbell earned his bachelor’s degree in public policy at Duke University and his M.B.A. at Harvard Business School.

What is Bradley L. Campbell's net worth?

The estimated net worth of Bradley L. Campbell is at least $7.41 million as of June 21st, 2022. Mr. Campbell owns 689,618 shares of Amicus Therapeutics stock worth more than $7,406,497 as of July 1st. This net worth approximation does not reflect any other assets that Mr. Campbell may own. Additionally, Mr. Campbell receives an annual salary of $947,800.00 as COO at Amicus Therapeutics. Learn More about Bradley L. Campbell's net worth.

How old is Bradley L. Campbell?

Mr. Campbell is currently 46 years old. There are 6 older executives and no younger executives at Amicus Therapeutics. The oldest executive at Amicus Therapeutics is Ms. Jayne C. Gershkowitz, Chief Patient Advocate, who is 65 years old. Learn More on Bradley L. Campbell's age.

What is Bradley L. Campbell's salary?

As the COO of Amicus Therapeutics, Inc., Mr. Campbell earned a total compensation package of $4,638,818.00 in 2020. Mr. Campbell earned a salary of $515,789.00, a bonus of $368,872.00, stock awards of $2,557,304.00, options awards of $1,163,159.00, and other compensation of $33,694.00.The highest earning executive at Amicus Therapeutics is Mr. John F. Crowley, Chairman & CEO, who commands a salary of $2,060,000.00 per year. Learn More on Bradley L. Campbell's salary.

How do I contact Bradley L. Campbell?

The corporate mailing address for Mr. Campbell and other Amicus Therapeutics executives is 1 Cedar Brook Drive, Cranbury NJ, 08512. Amicus Therapeutics can also be reached via phone at (215) 921-7600 and via email at [email protected] Learn More on Bradley L. Campbell's contact information.

Has Bradley L. Campbell been buying or selling shares of Amicus Therapeutics?

Bradley L. Campbell has not been actively trading shares of Amicus Therapeutics in the last ninety days. As far as recent transactions, on Friday, July 1st, 0 shares of BMO Capital Markets stock. Learn More on Bradley L. Campbell's trading history.

Who are Amicus Therapeutics' active insiders?

Amicus Therapeutics' insider roster includes Lynn Bleil (Director), Bradley Campbell (COO), Bradley Campbell (COO), John Crowley (CEO), John Crowley (CEO), Margaret Mcglynn (Director), Samantha Prout (Insider), and Burke Whitman (Director). Learn More on Amicus Therapeutics' active insiders.

Are insiders buying or selling shares of Amicus Therapeutics?

During the last year, Amicus Therapeutics insiders bought shares 5 times. They purchased a total of 7,500 shares worth more than $75,510.00. During the last year, insiders at the biopharmaceutical company sold shares 32 times. They sold a total of 466,979 shares worth more than $4,904,275.65. The most recent insider tranaction occured on June, 21st when COO Bradley L Campbell sold 16,410 shares worth more than $164,100.00. Insiders at Amicus Therapeutics own 2.1 % of the company. Learn More about insider trades at Amicus Therapeutics.

Information on this page was last updated on 6/21/2022.

Bradley L. Campbell Insider Trading History at Amicus Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/21/2022Sell16,410$10.00$164,100.00689,618View SEC Filing Icon  
3/18/2022Sell10,940$10.00$109,400.00View SEC Filing Icon  
1/3/2022Sell5,470$11.86$64,874.20View SEC Filing Icon  
12/22/2021Sell3,000$11.70$35,100.00View SEC Filing Icon  
12/1/2021Sell10,515$11.00$115,665.00View SEC Filing Icon  
11/1/2021Sell10,515$11.32$119,029.80View SEC Filing Icon  
10/1/2021Sell10,515$10.00$105,150.00View SEC Filing Icon  
9/1/2021Sell10,515$11.50$120,922.50View SEC Filing Icon  
8/5/2021Sell21,028$10.02$210,700.56View SEC Filing Icon  
6/7/2021Sell10,514$10.01$105,245.14436,397View SEC Filing Icon  
5/3/2021Sell10,514$10.27$107,978.78422,536View SEC Filing Icon  
4/1/2021Sell10,514$10.03$105,455.42389,371View SEC Filing Icon  
1/4/2021Sell10,514$22.17$233,095.38347,215View SEC Filing Icon  
12/1/2020Sell24,783$22.77$564,308.91363,547View SEC Filing Icon  
11/2/2020Sell24,782$17.87$442,854.34363,546View SEC Filing Icon  
9/28/2020Sell24,782$13.89$344,221.98363,546View SEC Filing Icon  
7/8/2020Sell2,500$16.01$40,025.00341,264View SEC Filing Icon  
7/1/2020Sell12,500$15.47$193,375.00351,264View SEC Filing Icon  
6/1/2020Sell17,502$12.66$221,575.32365,355View SEC Filing Icon  
5/26/2020Sell2,500$13.01$32,525.00357,855View SEC Filing Icon  
5/1/2020Sell17,503$11.33$198,308.99372,858View SEC Filing Icon  
4/7/2020Sell2,500$10.12$25,300.00365,358View SEC Filing Icon  
4/1/2020Sell15,003$9.09$136,377.27363,014View SEC Filing Icon  
3/5/2020Sell2,500$10.01$25,025.00358,014View SEC Filing Icon  
2/5/2020Sell2,500$10.01$25,025.00365,517View SEC Filing Icon  
2/3/2020Sell15,003$8.91$133,676.73378,020View SEC Filing Icon  
1/15/2020Sell5,064$10.35$52,412.40370,520View SEC Filing Icon  
1/9/2020Sell2,500$10.01$25,025.00347,695View SEC Filing Icon  
1/2/2020Sell22,127$9.58$211,976.66253,987View SEC Filing Icon  
1/22/2019Sell36,000$11.81$425,160.00275,360View SEC Filing Icon  
1/22/2018Sell32,500$15.92$517,400.00186,600View SEC Filing Icon  
3/2/2017Sell49,050$8.00$392,400.00127,475View SEC Filing Icon  
9/21/2015Sell13,001$16.78$218,156.78156,575View SEC Filing Icon  
6/19/2015Sell13,000$13.26$172,380.00View SEC Filing Icon  
11/25/2014Sell7,250$8.00$58,000.00View SEC Filing Icon  
8/25/2014Sell7,000$6.00$42,000.00View SEC Filing Icon  
8/20/2014Sell18,750$5.40$101,250.00View SEC Filing Icon  
See Full Table

Bradley L. Campbell Buying and Selling Activity at Amicus Therapeutics

This chart shows Bradley L Campbell's buying and selling at Amicus Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Amicus Therapeutics Company Overview

Amicus Therapeutics logo
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
Read More

Today's Range

Now: $10.74
Low: $10.59
High: $10.90

50 Day Range

MA: $8.13
Low: $6.23
High: $11.12

2 Week Range

Now: $10.74
Low: $5.91
High: $12.63

Volume

1,825,709 shs

Average Volume

3,552,592 shs

Market Capitalization

$3.01 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.41
Make Sure Your Alarm Is Set…
This early morning trade is constantly overlooked, but those who use it are retiring early!

Hi, I’m trading expert Dave Aquino and with my new guide, “How To Master The Retirement Trade”, you could be taking advantage of it as well!

The trade starts at 9:30EST…don’t be late!

Get a copy here!

>>>